TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Profound Medical ( (TSE:PRN) ) has provided an announcement.
Profound Medical Corp. has entered into an exclusive distribution agreement with Getz Healthcare to bring its TULSA-PRO system to Australia and New Zealand. This partnership is expected to enhance precision prostate care in these regions by offering an innovative, incision-free treatment option. The agreement marks a strategic expansion for Profound Medical, allowing them to tap into a significant market where prostate cancer is highly prevalent. The collaboration with Getz Healthcare, a leading distributor in Asia Pacific, aligns with Profound’s strategy to expand its global reach and strengthen its market position in prostate cancer treatment.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Spark’s Take on TSE:PRN Stock
According to Spark, TipRanks’ AI Analyst, TSE:PRN is a Neutral.
Profound Medical’s stock score reflects the company’s strong revenue growth and strategic potential, balanced by operational inefficiencies and financial challenges. Technical indicators suggest caution due to bearish trends, while valuation remains a concern with negative earnings. Positive earnings call sentiment and future growth prospects are encouraging, yet immediate operational improvements are necessary for sustained success.
To see Spark’s full report on TSE:PRN stock, click here.
More about Profound Medical
Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. Their primary product, TULSA-PRO, is a technology that combines real-time MRI, AI-enhanced planning, and robotically-driven ultrasound for prostate therapy. The company aims to make TULSA-PRO a mainstream treatment for various prostate conditions.
Average Trading Volume: 19,442
Technical Sentiment Signal: Hold
Current Market Cap: C$251.5M
Find detailed analytics on PRN stock on TipRanks’ Stock Analysis page.